Last reviewed · How we verify
BXQ-350
At a glance
| Generic name | BXQ-350 |
|---|---|
| Also known as | SapC-DOPS |
| Sponsor | Bexion Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- BXQ-350 Pharmacokinetic/Pharmacodynamic Study in Cancer Patients (EARLY_PHASE1)
- A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG) (PHASE1)
- Continued Treatment for Participants Enrolled in Studies of BXQ-350 (PHASE1)
- BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma (PHASE1, PHASE2)
- A Study of BXQ-350 in Children and Young Adults With Relapsed Solid Tumors (PHASE1)
- Phase 1 Study of BXQ-350 in Adult Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BXQ-350 CI brief — competitive landscape report
- BXQ-350 updates RSS · CI watch RSS
- Bexion Pharmaceuticals, Inc. portfolio CI